Vitamin C and Charcot-Marie-Tooth 1A: Pharmacokinetic considerations.

about

Therapeutic options in Charcot-Marie-Tooth diseases.Selected Micronutrients in Cognitive Decline Prevention and Therapy.

P2860

Q38363677-04DF5FC2-66AB-4DF5-909F-543137F0EFC2 Q38551719-3750AD20-4D7B-4224-9452-964C22DB546F

P2860

Vitamin C and Charcot-Marie-Tooth 1A: Pharmacokinetic considerations.

Item

http://www.wikidata.org/entity/Q36701520

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Vitamin C and Charcot-Marie-Tooth 1A: Pharmacokinetic considerations.

@ast

Vitamin C and Charcot-Marie-Tooth 1A: Pharmacokinetic considerations.

@en

type

Item

label

Vitamin C and Charcot-Marie-Tooth 1A: Pharmacokinetic considerations.

@ast

Vitamin C and Charcot-Marie-Tooth 1A: Pharmacokinetic considerations.

@en

prefLabel

Vitamin C and Charcot-Marie-Tooth 1A: Pharmacokinetic considerations.

@ast

Vitamin C and Charcot-Marie-Tooth 1A: Pharmacokinetic considerations.

@en

P1476

Vitamin C and Charcot-Marie-Tooth 1A: Pharmacokinetic considerations

@en

P2093

A Solari

http://www.w3.org/2001/XMLSchema#string

D Pareyson

http://www.w3.org/2001/XMLSchema#string

M M Reilly

http://www.w3.org/2001/XMLSchema#string

M Rimoldi

http://www.w3.org/2001/XMLSchema#string

for the CMT-TRIAAL & CMT-TRAUK Groups

http://www.w3.org/2001/XMLSchema#string

P2860

Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects

Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance

Dose translation from animal to human studies revisited

Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial

Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans.

Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease.

Vitamin C pharmacokinetics: implications for oral and intravenous use.

Experimental scurvy in man.

The new US Dietary Reference Intakes for vitamins C and E.

Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?

P304

10-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.PHANU.2012.10.001

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Francesco Visioli

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23525455

http://www.w3.org/2001/XMLSchema#string

P921

vitamin C

P932

3603168

http://www.w3.org/2001/XMLSchema#string

Vitamin C and Charcot-Marie-Tooth 1A: Pharmacokinetic considerations.

about

P2860

P2860

Vitamin C and Charcot-Marie-Tooth 1A: Pharmacokinetic considerations.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932